fashion -WSS

fashion

author：leisure time 2025-09-30 00:03:47 - browse：9

The FDA building -- First Opinion coverage from STAT — Adobe

U.S. regulators on Wednesday approved the first treatment for an ultra-rare disease that causes people to grow bone where it otherwise shouldn’t be, extending an option to patients who have been advocating for access to the medicine.

The treatment, an oral medication that will be marketed as Sohonos, faced some questions about the quality of its data, and was rejected earlier this year by European regulators. But in approving the drug for the treatment of fibrodysplasia ossificans progressiva, or FOP, the Food and Drug Administration concluded that Sohonos’ benefits outweigh its risks.

“I just closed my eyes and looked up to the skies, like ‘Thank you, God,’” said Suzanne Hollywood, whose teenage son, Joey, has been receiving the drug in a clinical trial. “It’s far from perfect, but I’m thrilled for my son, for his future, and for the kids getting diagnosed who might not have to experience what others had to.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： Organ aging and disease risk measured by new blood test

WSS

A new nitrogen execution bill also undermines medical licensing

As biotech industry slumps, bioscience job market is upside down

As biotech industry slumps, bioscience job market is upside down

Readout Newsletter: The latest in Pfizer, Moderna, and Sanofi

Is mRNA technology the right fit for flu shots? Experts aren’t so sure

NIH study of ME/CFS points to clear biological hallmarks

hotspot

fashion

hotspot

Moonlake's readout produced a cash windfall. Risks remain

FDA investigates CAR

Sports medicine is finally prioritizing gender equality

Medicare inequities exacerbate Puerto Rico’s health disparities

Virginia high school admissions case could be legal follow

Ed Silverman on new gene therapies, biosimilars, coffee, and more

23andMe had bad news about my health. I wish a person had delivered it

Alabama IVF ruling threatens families facing fatal genetic disease

Heart attack and stroke risk calculators need revising

Cigna, Humana reportedly in talks to merge

entertainment

ReNAgade cuts staff seven months after raising $300 million

Readout LOUD podcast: Humira legacy, AbbVie CEO's retirement

FDA investigates CAR

U.K. Biobank has 500,000 peoples' genome sequences available

Alabama IVF ruling threatens families facing fatal genetic disease

Antivenom research: Lessons from HIV applied in search for universal antidote

explore

focus

hotspot

focus